NotebookLM: Federal Regulation of Drugs II

1. Requirements for Pharmacy Compounding According to the FDCA

Retail Pharmacy Exemption (§ 510(g)): Pharmacies are exempt from registering as manufacturers if they do not manufacture or compound drugs for sale outside the regular course of their business of dispensing at retail^[1].

General Compounding Standards:

• Compounded products must comply with USP standards (such as USP <795> for nonsterile, USP <797> for sterile, and USP <800> for hazardous drugs)^[2][3].

• Compounding bulk substances must be manufactured by FDA-registered entities^[2].

• Products must not be a copy of a commercially available product, made from drugs withdrawn for safety/efficacy, or made from drugs listed as difficult to compound^[2].

Traditional Compounding (§ 503A):

• Limited to extemporaneous preparation of reasonable quantities pursuant to an individual prescription (or limited compounding in anticipation of a prescription)^[4].

• Must be prepared by a licensed pharmacist or physician^[4].

• Interstate distribution is capped at 5% of total prescriptions dispensed unless a state-FDA agreement exists^[4][5].

• Exempt from: Current Good Manufacturing Practice (cGMP) requirements, premarket approval, and "adequate directions for use" labeling^[5].

Outsourcing Facilities (§ 503B):

• Applies to facilities (not required to be licensed pharmacies) registered with the FDA to compound sterile products under direct supervision of a licensed pharmacist^[4][6].

• May compound with or without patient-specific prescriptions^[4].

• Exempt from: Premarket approval and "adequate directions for use" labeling^[5].

• Must comply with: cGMP requirements, FDA inspections, FDCA labeling rules, and adverse event reporting^[5][6]. Resale or transfer by third parties (e.g., wholesalers selling to pharmacies) is strictly prohibited^[5][6].

2. Definition of "Orphan Drug"

• Under the Orphan Drug Act (1983), an orphan drug is defined as a drug intended to treat a rare disease or condition affecting fewer than 200,000 people in the United States^[7].

• Because small patient populations make R&D and clinical trials cost-prohibitive, the Act provides tax incentives and exclusive licensing rights to encourage manufacturers to develop these treatments^[7][8].

3. Poison Prevention Packaging Act (PPPA) in Pharmacy Practice & Packaging

• Intent & Scope: Administered by the Consumer Product Safety Commission (CPSC) to protect children under 5 years old from accidental poisonings from household substances, including OTC and prescription drugs^[9].

• Packaging Standard: Containers must be child-resistant—defined as 80% of children under 5 being unable to open it, while 90% of adults can open it^[9].

• Container Reuse: Reusing prescription containers is prohibited unless made of glass or threaded plastic, and even then, a new safety closure must be used^[9].

• Exemptions to PPPA:

  • Prescriber request (applies to individual prescriptions)^[10].

  • Patient request (patients may issue a blanket opt-out in writing for all prescription drugs)^[10].

  • Institutionalized patients (where medications are administered by employees)^[10].

  • Specific drug exemptions: E.g., sublingual nitroglycerin, or sublingual and chewable isosorbide dinitrate^[10].

  • OTC Packaging: Manufacturers may market one size in noncompliant packaging if clearly labeled "This package for households w/o young children"^[10].

none

none